October 29, 2026
Read the full article.BERKELEY, Calif., October 29, 2026 -- IMVARIA, an applied clinical AI company, announced today that it has been selected to participate in the 2026-2027 National Cancer Institute Small Business Innovation Research (NCI SBIR) Investor Initiatives program. IMVARIA is one of 30 companies selected from 152 applicants through a review by private investors and strategic partners.
The program connects NCI SBIR-funded companies with investors and strategic partners through national investor showcases. IMVARIA will present at MedTech Strategist's Innovation Summit San Diego on November 3, 2026.
IMVARIA's platform applies FDA-authorized AI technology to medical record and imaging data. The company has two FDA-authorized technologies in market, and NCI SBIR support is advancing its next product in early-stage lung cancer.
"There is more signal in a person's medical record and imaging data," said Joshua Reicher, MD, co-founder and CEO of IMVARIA. "This program gives us a platform to meet investors and partners as we scale commercialization and bring our work to more patients."
About IMVARIA
IMVARIA is an applied clinical AI company bringing FDA-authorized AI technology to physicians and their patients. Learn more at imvaria.com.
About NCI SBIR Investor Initiatives
The NCI SBIR Investor Initiatives program connects selected NCI SBIR- and STTR-funded companies with potential investors. Learn more at sbir.cancer.gov/commercialization/business/investor-initiatives.
Media contact: Michael Muelly, MD, CFO | info@imvaria.com | imvaria.com
